Triazole derivatives as Wnt signaling pathway inhibitors

US9403812B2 · kind B2 · utility

Assignee

• Oslo University Hospital HF · NO

Inventors

• Daniel Holsworth · San Diego, US
• Jo Waaler · Oslo, NO
• Ondrej Machon · Praha, CZ
• Stefan Krauss · Eidsvoll verk, NO
• Andrey Edward Voronkov · Oslo, NO

Key dates

• Filing date: Jun 29, 2015
• Grant date: Aug 2, 2016
• Expiry date: Jun 29, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy:Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway and increased presence of nuclear β-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.